SavedAdd your journal

Journals / MN Kardiyoloji / 2002 / Cilt: 9 - Sayı: 1

Evaluation of effect of doxazosin on cardiovascular risk factors in hypertensive patients with non-insulin dependent diabetes mellitus

İnsülin bağımlı olmayan hipertansif diyabetik hastalarda doksazosinin kardiyovasküler risk faktörleri üzerine olan etkilerinin değerlendirilmesi

Mustafa YILDIZ
Bülent ÖZTÜRK
Murat İNNİCE
Güler TÜRKEŞ
Yüksel ALTUNTAŞ
Pages
37–40
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Beneficial effects on pulse wave velocity, microalbuminuria and lipid profile makes doxazosin a good alternative in hypertensive patients with non-insulin dependent diabetes mellitus.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: The aim of the present study was to investigate the effect of doxazosin on pulse wave velocity and microalbuminuria in hypertensive patients with non-insulin dependent diabetes mellitus.
📊
Key Findings & Data:MATERIAL AND METHODS: Doxazosin (2-4 mg) was given to 85 patients with non-insulin dependent diabetes mellitus (age 60 + 10.3 years, 37-75) for a period of 8 weeks.
💡
Conclusion & Impact:Beneficial effects on pulse wave velocity, microalbuminuria and lipid profile makes doxazosin a good alternative in hypertensive patients with non-insulin dependent diabetes mellitus.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Diabetes mellitus · insülin bağımsız · Doksazosin

Abstract

AIM: The aim of the present study was to investigate the effect of doxazosin on pulse wave velocity and microalbuminuria in hypertensive patients with non-insulin dependent diabetes mellitus. MATERIAL AND METHODS: Doxazosin (2-4 mg) was given to 85 patients with non-insulin dependent diabetes mellitus (age 60 + 10.3 years, 37-75) for a period of 8 weeks. Pulse wave velocity were measured with Complior system (APTIVA IBM). RESULTS: Systolic and diastolic blood pressures, HbA1c, cholesterol, pulse wave velocity and microalbuminuria levels were significantly decreased from initial values (p<0.0001, p<0.0001, p=0.02, p=0.003, p<0.0001, p=0.01 respectively). However, there was no significant change in creatinine, glucose, HDL and LDL cholesterol levels (p=0.40, p=0.06, p=0.61, p=0.26 respectively). CONCLUSION: Doxazosin is effective and well tolerated in hypertensive patients with non-insulin dependent diabetes mellitus. It has no adverse effect on glucose metabolism. Beneficial effects on pulse wave velocity, microalbuminuria and lipid profile makes doxazosin a good alternative in hypertensive patients with non-insulin dependent diabetes mellitus.

Özet

AMAÇ: Bu çalışmada bir selektif alfa-1 adrenoseptör antagonisti olan doksazosinin, insüline bağımlı olmayan hipertansif diyabetes mellituslu hastalarda nabız dalga hızı ve mikroalbuminüri gibi çeşitli kardiyovasküler risk faktörleri üzerine olan etkileri araştırıldı. GEREÇ ve YÖNTEM: Yaşları 37-75 arasında değişen (ortalama 60 + 10.3 yıl) 85 insüline bağımlı olmayan hipertansif diyabetes mellituslu hastaya 8 hafta süre ile doksazosin 2-4 mg verildi. Çeşitli klinik ve biyokimyasal parametreler belirlendi. Nabız dalga hızı ölçümleri Complior sistemi (APTIVA IBM) ile yapıldı. BULGULAR: Sistolik kan basıncı, diyastolik kan basıncı, HbA1c, kolesterol, nabız dalga hızı ve mikroalbuminüri seviyeleri tedavi bitiminde başlangıç değerlerine göre anlamlı olarak düşük bulundu ( sırası ile p<0.0001, p<0.0001, p=0.02, p=0.003, p<0.0001 ve p=0.01). Kreatinin, kan şekeri, HDL ve LDL kolesterol seviyelerinde anlamlı değişiklik saptanmadı ( sırası ile p=0.40, p=0.06, p=0.61, p=0.26). SONUÇ: Sonuç olarak doksazosin insülin bağımlı olmayan hipertansif diyabetik hastaların tedavisinde etkilidir ve iyi tolere edilmektedir. Glikoz metabolizması üzerinde olumsuz etkiye sahip olmaması, nabız dalga hızı, mikroalbuminüri, hipertansiyon ve lipid profili üzerindeki olumlu etkileri, diyabetik hipertansif hastalarda tedavi seçimi yaparken göz önünde bulundurulması gereken özellikleridir.

🔖

Cite This Article

YILDIZ, M., ÖZTÜRK, B., İNNİCE, M., TÜRKEŞ, G., ALTUNTAŞ, Y. (2002). Evaluation of effect of doxazosin on cardiovascular risk factors in hypertensive patients with non-insulin dependent diabetes mellitus. MN Kardiyoloji, Cilt: 9 - Sayı: 1, 37–40. https://ajindex.com/articles/297644

References (12)

  1. Multiple risk factor intervention trial: Risk factor changes and mortality results. JAMA 1982; 248:1465-77.
  2. Lehman ED, Parker JR, Hopkins KD, Taylor MG, Gosling RG. Validation and reproductibility of pressure corrected aortic distensibility measurements using pulse wave velocity Doppler ultrasound. J Biomed Engl 1993; 15:221-8. Laurent P. Etude de la vitesse de propagation de l'onde de pouls: de la recherce experimental a la pratique clinique (these). Üniversite de Bordeaux; 1994.
  3. Yılmaz C, Yılmaz M. T., İmamoğlu Ş. Diabetes Mellitus 2000, İstanbul: Gri Tasarım 2000: 161. Esansiyel Hipertansiyon, Sol Ventrikül Hipertrofisi, Diyabetik Hipertansiyon ve Doksâzosin, Ankara:
  4. Hekimler Yayın Birliği, MedicoGraphics Ajans ve Matbaası 1996; 96. Güncel Diyabet Tedavisi, Galenos 1997; 1:40. Johansen PL, Hjermann I, Bjarne Ml, Thaolow E. Selective alpha-1 ınhibitors: First or second-line antihypertansive agents. Cardiology 1993;83:150-9. Brown MJ. Efficacy and tolerance of doxazosin: A review. Journal of Human Hypertension 1990; 4(suppl. 3):34-8.
  5. Corral JL, Lopez NG, Pocerelli A, Rincon LA, Teran VD. Doxazosin in the treatment of mild or moderete essential hypertension: An echocardiographic study. Am Heart J 1991; 121:352-6.
  6. Halme I, Fauchold P, Rugstad HE, Stokke HP. Preliminary results of the Norwegian Doxazosin Postmarketing Surveillance Study: A twelve week experience. Am Heart J 1991; 121:260-7.
  7. Giorda C, Appendino M: Effects of doxazosin, a selective alpha- 1 inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. Metab Clin Exp 1993; 42:1440-2.
  8. Feher MD, Henderson AD, Wadsworth J. Alpha blocker therapy: A possible advance in the treatment of diabetic hypertension- results of a cross- over study of doxazosin and atenolol monotherapy in hypertensive non- insulin dependent diabetic subjects. J Hum Hypertens 1990; 4:571-7.
  9. Kageyama S, Yamamoto J, Mimura A, Sakurai T, Ishibashi H, Aihara K, et al. Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther 1993; 15:829-37.
  10. Mattock MB, Morrish NJ, Viberti GC, Keen H, Fitzgerald AP Jackson G. Diabetes 1992; 41:736-41.
  11. Christiane M. E, Uwe H, Nils H, Norbert B,Teut R. Microalbuminuria in Essential Hypertension. Hypertens 1993; 21:810-5.
  12. Asmar R, Journo HJ, Lacolley PJ, Santoni JP, Billaud E, Levy B, et al.Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. J Hypertens 1988; 6 Suppl 3:33-